Breast cancer biomarkers and molecular medicine

Expert Review of Molecular Diagnostics

Volumn 3, Issue 5, 2003, Pages 573-585

  Ross, Jeffrey S ^a,b   Linette, Gerald P ^b,c   Stec, James ^b   Clark, Edwin ^b   Ayers, Mark ^b   Leschly, Nick ^b   Symmans, W Fraser ^d   Hortobagyi, Gabriel N ^d   Pusztai, Lajos ^d  

^a ALBANY MEDICAL COLLEGE   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Diagnosis; DNA ploidy; EGFR; HER 2 neu; Ki 67; Micrometastasis; Predisposition; Prognosis; Screening

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; CYCLIN DEPENDENT KINASE; CYCLIN E; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; INSULIN; KI 67 ANTIGEN; MAMMOGLOBIN; MASPIN; MESSENGER RNA; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN P21; PROTEIN P27; PROTEIN TYROSINE KINASE; PROTEINASE; TELOMERASE; TRANSCRIPTION FACTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; ASPIRATION BIOPSY; ASSAY; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SCREENING; CANCER SUSCEPTIBILITY; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; CYTOGENETICS; DNA METHYLATION; DNA MICROARRAY; DNA REPAIR; DNA TRANSCRIPTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; METASTASIS; ONCOGENE; ONCOGENE NEU; PLOIDY; POLYMERASE CHAIN REACTION; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR SUPPRESSOR GENE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; FEMALE; GENES, ERBB-2; GENETIC PREDISPOSITION TO DISEASE; GROWTH SUBSTANCES; HUMANS; MASS SCREENING; MOLECULAR DIAGNOSTIC TECHNIQUES; PROGNOSIS; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL;

EID: 0042822251     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.3.5.573     Document Type: Review

References (160)

1. Lacey JV Jr, Devesa SS, Brinton LA. Recent trends in breast cancer incidence and mortality. Environ. Mol. Mutagen. 39, 82-88 (2002).
2. Frank TS, Critchfield GC. Hereditary risk of women's cancers. Best Pract. Res. Clin. Obstet. Gynaecol. 16, 703-713 (2002).
3. Peto J. Breast cancer susceptibility: a new look at an old model. Cancer Cell 1, 411-412 (2002).
4. Rebbeck TR. The contribution of inherited genotype to breast cancer. Breast Cancer Res. 4, 85-89 (2002).
5. de Jong MM, Nolte IM, te Meerman GJ et al. Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J. Med. Genet. 39, 225-242 (2002).
6. Hayes DE Serum (circulating) tumor markers for breast cancer. Recent Results Cancer Res. 140, 101-113 (1996).
7. O'Brien N, Maguire TM, O'Donovan N et al. Mammaglobin: a promising marker for breast cancer. Clin. Chem 48, 1362-1364 (2002).
8. Maass N, Nagasaki K, Ziebart M et al. Expression and regulation of tumor suppressor gene maspin in breast cancer. Clin. Breast Cancer 3, 281-287 (2002).
9. Watson MA, Dintzis S, Darrow CM et al. Mammaglobin expression in primary, metastatic and occult breast cancer. Cancer Res. 59, 3028-3031 (1999).
10. Li J, Zhang Z, Rosenzweig J et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48, 1296-1304 (2002).
11. Kvalheim G. Detection of occult tumour cells in bone marrow and blood in breast cancer patients: methods and clinical significance. Acta Oncol. 35(Suppl. 8), 13-18 (1996).
12. Hu XC, Chow LW. Detection of circulating breast cancer cells by reverse transcriptase polymerase chain reaction (RT-PCR). Eur. J. Surg. Oncol. 26, 530-535 (2000).
13. Dunmire V, Wu C, Symmans WF, Zhang W. Increased yield of total RNA from fine-needle aspirates for use in expression microarray analysis. Biotechniques 33, 890-896 (2002).
14. Assersohn L, Gangi L, Zhao Y et al. The feasibility of using fine needle aspiration from primary breast cancers for cDNA microarray analyses. Clin. Cancer Res. 8, 794-801 (2002). Demonstrates that the fine needle aspiration technique can be used to generate sufficient RNA for genomic analysis which may prove critical for monitoring future pharmacogenomic markers.
15. Sotiriou C, Powles TJ, Dowsett M et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 4, R3 (2002).
16. King EB, Chew KL, Petrakis NL et al. Nipple aspirate cytology for the study of breast cancer precursors. J. Natl Cancer Inst. 7, 1115-1121 (1983).
17. Sauter ER, Zhu W, Fan XJ et al. Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer. Br. J. Cancer 86, 1440-1443 (2002).
18. Lee AK, DeLellis RA, Rosen PP et al. α-lactalbumin as an immunohistochemical marker for metastatic breast carcinomas. Am. J Surg. Pathol. 8, 93-100 (1994).
19. Hilborne LH, Cheng L, Nieburg RK et al. Evaluation of the antibody to milk fat globule antigen in the detection of metastatic carcinoma in plural, pericardial and peritoneal fluids. Acta Cytol. 30, 245-250 (1986).
20. Maass N, Nagasaki K, Ziebart M et al. Expression and regulation of tumor suppressor gene maspin in breast cancer. Clin. Breast Cancer 3, 281-287 (2002).
21. Corradini P, Voena C, Astolfi M et al. Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer. Ann. Oncol. 12, 1693-1698 (2001).
22. Funke I, Schraut W. Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. J. Clin. Oncol. 16, 557-566 (1998).
23. Noguchi M. Therapeutic relevance of breast cancer micrometastases in sentinel lymph nodes. Br. J. Surg. 89, 1505-1515 (2002). Thorough review of this controversial subject.
24. Braun S, Pantel K. Micrometastatic bone marrow involvement: detection and prognostic significance. Med. Oncol. 16, 154-165 (1999).
25. Yeatman TJ, Cox CE. The significance of breast cancer lymph node micrometastases. Surg. Oncol. Clin. N. Am 8, 481-496 (1999).
26. Mitas M, Mikhitarian K, Walters C et al. Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. Int. J. Cancer 93, 162-171 (2001).
27. Hilsenbeck SG, Clark GM, McGuire WL. Why do so many prognostic factors fail to pan out? Breast Cancer Res. Treat. 22, 197-206 (1992). Landmark overview of the future application of prognostic tests for the management of breast cancer.
28. Gebhart E, Bruderlein S, Augustus M et al. Cytogenetic studies on human breast carcinomas. Breast Cancer Res. Treat 8, 125-138 (1986).
29. Adeyinka A, Mertens F, Idvall I et al. Cytogenetic findings in invasive breast carcinomas with prognostically favourable histology: a less complex karyorypic pattern? Int. J. Cancer 79, 361-364 (1998).
30. Monni O, Hyman E, Mousses S et al. From chromosomal alterations to target genes for therapy: integrating cytogenetic and functional genomic views of the breast cancer genome. Semin. Cancer Biol. 11, 395-401 (2001).
31. Isola JJ, Kallioniemi O-P, Chu LW et al. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am. J. Pathol. 147, 905-911 (1995).
32. Ross JS. DNA ploidy and cell cycle analysis in pathology. Igaku-Shoin Publishing, NY, USA, 54-55 (1996).
33. Bast RC Jr, Ravdin P, Hayes DF et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 19, 1865-1878 (2001).
34. Hammond ME, Fitzgibbons PL, Compton CC et al. College of American Pathologists Conference XXXV. solid tumor prognostic factors: which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants. Arch. Pathol. Lab. Med. 124, 958-965 (2000).
35. MacGrogan G, Jollet I, Huet S et al. Comparison of quantitative and semiquantitative methods of assessing MIB-1 with the S-phase fraction in breast carcinoma. Mod. Pathol. 10, 769-776 (1997).
36. Wolman SR, Pauley RJ, Mohamed AN et al. Genetic markers as prognostic indicators in breast cancer. Cancer 70, 1765-1774 (1992).
37. Steeg PS, Zhou Q. Cyclins and breast cancer. Breast Cancer Res. Treat. 52, 17-28 (1998).
38. Weinstat-Saslow D, Merino MJ, Manrow RE et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nature Med. 1, 1257-1260 (1995).
39. Keyomarsi K, Tucker SL, Buchholz TA et al. Cyclin E and survival in patients with breast cancer. N. Engl. J. Med. 347, 1566-1575 (2002).
40. Keyomarsi K, O'Leary N, Molnar G et al. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res. 54, 380-385 (1994).
41. Cafffo O, Doglioni C, Veronese S et al. Prognostic value of p21 (WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin. Cancer Res. 2, 1591-1599 (1996).
42. Oh YL, Choi JS, Song SY et al. Expression of p21Waf1, p27Kip1 and cydin D1 proteins in breast ductal carcinoma in situ: relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status. Pathol. Int. 51, 94-99 (2001).
43. Gohring UJ, Bersch A, Becker M et al. p21(waf) correlates with DNA replication but not with prognosis in invasive breast cancer. J. Clin. Pathol. 54, 866-870 (2001).
44. Lau R, Grimson R, Sansome C et al. Low levels of cell cycle inhibitor p27kip1 combined with high levels of Ki-67 predict shortened disease-free survival in T1 and T2 invasive breast carcinomas. Int. J. Oncol. 18(1), 17-23 (2001).
45. Barbareschi M. p27 expression: a cyclin-dependent kinase inhibitor in breast carcinoma. Adv. Clin. Path. 3(4), 119-127 (1999).
46. Barbareschi M, van Tinteren H, Mauri FA et al. p27 (kip1) expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up. Int. J. Cancer. 89, 236-241 (2000).
47. Leivonen M, Nordling S, Lundin J et al. p27 expression correlates with short-term but not with long-term prognosis in breast cancer. Breast Cancer Res. Treat. 6, 15-22 (2001).
48. Nohara T, Ryo T, Iwamoto S et al. Expression of cell-cycle regulator p27 is correlated to the prognosis and ER expression in breast carcinoma patients. Oncology 60, 94-100 (2001).
49. Signoretti S, Di Marcotullio L, Richardson A et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J. Clin. Invest. 110, 633-641 (2002).
50. Nicholoson S, Richard J, Sainsbury C et al. Epidermal growth factor receptor (EGFR): results of a six-year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br. J. Cancer 63, 146-150 (1991).
51. Castellani R, Visscher EW, Wykes S et al. Interaction of transforming growth factor-α and epidermal growth factor receptor in breast carcinoma. Cancer 73, 344-349 (1994).
52. Tsutsui S, Kataoka A, Ohno S et al. Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin. Cancer Res. 8, 3454-3460 (2002). Overview of the EGFR situation in breast cancer and why it is not analogous to the HER-2/neu story.
53. Ferrero JM, Ramaioli A, Largillier R et al. Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up. Ann. Oncol. 12, 841-846 (2001).
54. Suo Z, Risberg B, Karlsson MG et al. The expression of EGFR family ligands in breast carcinomas. Int. J. Surg. Pathol. 10, 91-99 (2002).
55. Morris C. The role of EGFR-directed therapy in the treatment of breast cancer. Breast Cancer Res. Treat. 75 (Suppl. 1) S51-S52 (2002).
56. Solbach C, Roller M, Ahr A et al. Antiepidermal growth factor receptor-antibody therapy for treatment of breast cancer. Int. J. Cancer 101, 390-394 (2002).
57. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am. J. Clin. Pathol. 112(1 Suppl. 1), S53-S67 (1999).
58. Schnitt SJ, Jacobs TW. Current status of HER2 testing: caught between a rock and a hard place. Am. J. Clin. Pathol. 116, 806-810 (2001).
59. Hayes DF, Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin. Oncol. 29, 231-245 (2002).
60. Masood S, Bui MM. Prognostic and predictive value of HER2/neu oncogene in breast cancer. Microsc. Res. Tech. 59, 102-108 (2002).
61. Paik S, Bryant J, Tan-Chiu E et al. Real-world performance of HER2 testing: National Surgical Adjuvant Breast and Bowel Project experience. J. Natl Cancer Inst. 94, 852-854 (2002). Paper which has cautioned oncologists on accuracy of immunohistochemistry (IHC)-based HER-2/neu assays.
62. Wang S, Saboorian MH, Frenkel EP et al. Assessment of HER-2/neu status in breast cancer. Automated cellular imaging system (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am. J. Clin. Pathol. 116, 495-503 (2001).
63. Thor AD, Liu S, Edgerton S et al. Activation (tyrosine phosphorylation) of erbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J. Clin. Oncol. 18, 3230-3239 (2000).
64. Wang S, Saboorian MH, Frenkel E et al. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridization assays. J. Clin. Pathol. 53, 374-381 (2000).
65. Tanner M, Gancberg D, Di Leo A et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am. J. Pathol. 157, 1467-1472 (2000).
66. Zhao J, Wu R, Au A et al. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod. Pathol. 15, 657-665 (2002).
67. Pawlowski V, Revillion F, Hornez L et al. A real-time one-step reverse transcriptase-polymerase chain reaction method to quantify c-erbB-2 expression in human breast cancer. Cancer Detect. Prev. 24, 212-223 (2000).
68. Joensuu H, Isola J, Lundin M et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pt1n0m0 breast cancer: a nationwide population-based study. Clin. Cancer Res. 9, 923-930 (2003). Study which uses two unique approaches: tissue microarrays and the chromogenic in situ hybridization (CISH) technique. CISH status was an independent prognostic factor and outperformed estrogen receptor (ER) status.
69. Bieche I, Onody P, Laurendeau I et al. Real-time reverse transcription-PCR assay for future management of erb2-based clinical applications. Clin. Chem. 45, 1148-1156 (1999).
70. Tubbs RR, Pettay JD, Roche PC et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J. Clin. Oncol. 19, 2714-2721 (2001).
71. Pawlowski V, Revillion F, Hebbar M et al. Prognostic value of the Type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin. Cancer Res. 6, 4217-4225 (2000).
72. Huston JS, George AJ. Engineered antibodies take center stage. Hum. Antibodies 10, 127-142 (2001).
73. Hortobagyi GN. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin. Oncol. 28, 43-47 (2001).
74. McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62, 209-243 (2002).
75. Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1, 117-123 (2002).
76. Ligibel JA, Winer EE Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin. Oncol. 29, 38-43 (2002).
77. Roche PC, Ingle JN. Increased HER2 with US Food and Drug Administration-approved antibody. J. Clin. Oncol. 17(1), 434 (1999).
78. Mass RD, Press MF, Anderson S et al. Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proc. Am. Soc. Clin. Oncol. 20 (2001) (Abstract 85). Although still not published asa full-length manuscript, this abstract describes the Genentech retrospective study that indicated that fine needle aspiration (FISH) was a better predictor of trastuzumab response than IHC.
79. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002).
80. Nichols DW, Wolff DJ, Self S et al. A testing algorithm for determination of HER2 status in patients with breast cancer. Ann. Clin. Lab. Sci. 32, 3-11 (2002).
81. Kobayashi M, Ooi A, Oda Y et al. Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues. Hum. Pathol. 33, 21-28 (2002).
82. Seidman AD, Fornier MN, Esteva FJ et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J. Clin. Oncol. 19, 2587-2595 (2001).
83. Schnitt SJ, Jacobs TW. Current status of HER2 testing: caught between a rock and a hard place. Am. J. Clin. Pathol. 116, 806-810 (2001).
84. Press MF, Slamon DJ, Flom KJ et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J. Clin. Oncol. 20, 3095-3105 (2002).
85. Piccart M, Lohrisch C, Di Leo A et al. The predictive value of HER2 in breast cancer. Oncology 61(Suppl. 2), 73-82 (2001).
86. Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr. Relat. Cancer 8, 191-195 (2001).
87. Muss HB. Role of adjuvant endocrine therapy in early-stage breast cancer. Semin. Oncol. 28, 313-321 (2001).
88. Schmid P, Wischnewsky MB, Sezer O et al. Prediction of response to hormonal treatment in metastatic breast cancer. Oncology 63, 309-316 (2002).
89. Nunes RA, Harris LN. The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin. Breast Cancer 3, 125-135 (2002).
90. Konecny G, Pauletti G, Pegram M et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J. Natl Cancer Inst. 95(2), 142-153 (2003).
91. Sjogren S, Inganas M, Lindgren A et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J. Clin. Oncol. 16, 462-469 (1998).
92. Carlomagno C, Perrone F, Gallo C et al. C-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without ancillary lymph node metastases. J. Clin. Oncol. 14, 2702-2708 (1996).
93. Burke HB, Hoang A, Iglehart JD et al. Predicting response to adjuvant and radiation therapy in patients with early-stage breast carcinoma. Cancer 82, 874-877 (1998).
94. Elledge RM, Green S, Ciocca D et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group study. Clin. Cancer Res. 4, 7-12 (1998).
95. De Placido S, De Laurentiis M, Carlomagno C et al. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin. Cancer Res. 9, 1039-1046 (2003).
96. Ravdin PM, Green S, Albain V et al. Initial report of the SWOG biological correlative study of c-erbB2 expression as a predictor of outcome in a trial comparing adjuvant CAF with tamoxifen alone. Proc. Am. Soc. Clin. Oncol. 17, 97a (1998).
97. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J. Clin. Oncol. 19, 3808-3816 (2001). Interesting study awaiting confirmation in prospective trials that HER-2/neu status can drive the selection of antiestrogen therapy.
98. Berns EM, Foekens JA, vanStaveren IL et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159, 11-18 (1995).
99. Sparano JA. Taxanes for breast cancer: an evidence-based review of randomized Phase II and Phase III trials. Clin. Breast Cancer 1, 32-40 (2000).
100. Yu D. Mechanisms of erbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in erbB2-overexpressing breast cancers. Semin. Oncol. 28(5 Suppl. 16), 12-17 (2001).
101. Menard S, Valagussa P, Pilotti S et al. Response to cyclophosphamide, methotrexate and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J. Clin. Oncol. 19, 329-335 (2001).
102. Van Poznak C, Tan L, Panageas KS et al. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J. Clin. Oncol. 20, 2319-2326 (2002).
103. Baselga J, Seidman AD, Rosen PP et al. HER-2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology 11, 43-48 (1997).
104. Kim R, Tanabe K, Uchida Y. The role of HER-2 oncoprotein in drug-sensitivity in breast cancer. Oncol. Rep. 9, 3-9 (2002).
105. Hamilton A, Larsimont D, Paridaens R et al. A study of the value of p53, HER2 and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. Clin. Breast Cancer 1, 233-240 (2000).
106. Di Leo A, Larsimont D, Gancberg D et al. HER-2 and topoisomerase IIα as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann. Oncol. 12, 1081-1089 (2001).
107. Petit T, Borel C, Ghnassia JP et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin. Cancer Res. 7, 1577-1581 (2001).
108. Harris LN, Yang L, Liotcheva V et al. Induction of topoisomerase II activity after erbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin. Cancer Res. 7, 1497-1504 (2001).
109. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15(5), 537-547 (1997).
110. Jarvinen TA, Holli K, Kuukasjarvi T et al. Predictive value of topoisomerase IIα and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br. J. Cancer 77, 2267-2273 (1998).
111. Depowski PL, Rosenthal SI, Brien TP et al. Topoisomerase IIα expression in breast cancer: correlation with outcome variables. Mod. Pathol. 13, 542-547 (2000).
112. Jarvinen TA, Tanner M, Rantanen V et al. Amplification and deletion of topoisomerase IIα associate with erbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol. 156, 839-847 (2000).
113. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIα in primary and metastatic breast cancer. Cancer Res. 61, 5345-5348 (2001).
114. Harris LN, Yang L, Liotcheva V et al. Induction of topoisomerase II activity after erbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin. Cancer Res. 7, 1497-1504 (2001).
115. Di Leo A, Gancberg D, Larsimont D et al. HER-2 amplification and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate and 5-fluorouracil. Clin. Cancer Res. 8, 1107-1116 (2002).
116. Coon JS, Marcus E, Gupta-Burt S et al. Amplification and overexpression of topoisomerase IIα predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res. 8, 1061-1067 (2002).
117. Haffty BG, Brown F, Carter D et al. Evaluation of HER-2/neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: a case-control study. Int. J. Radiat. Oncol. Biol. Phys. 35, 751-757 (1996).
118. Lipton A, Ali SM, Leitzel K et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J. Clin. Oncol. 20, 1467-1472 (2002).
119. Volas GH, Leitzel K, Teramoto Y et al. Serial serum C-erbB-2 levels in patients with breast carcinoma. Cancer 78, 267-272 (1996).
120. Bose S, Lesser ML, Norton L et al. Immunophenotype of intraductal carcinoma. Arch. Pathol. Lab. Med. 120, 81-85 (1996).
121. Moreno A, Lloveras B, Figueras A et al. Ductal carcinoma in situ of the breast: correlation between histologic classification and biologic markers. Mod. Pathol. 10, 1088-1092 (1997).
122. Mack L, Kerkzelit N, Doig G et al. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, C-erbB-2, bcl2 and ki-67. Hum. Pathol. 28, 974-979 (1997).
123. Wolber RA, DuPuis BA, Wick MR. Expression of c-erbB-2 oncoprotein in mammary and extramammary Paget's disease. Am. J. Clin. Pathol. 96, 243-247 (1991).
124. Fu W, Lobocki CA, Silberberg BK et al. Molecular markers in Paget's disease of the breast. J. Surg. Oncol. 77, 171-178 (2001).
125. Masood S, Bui MM. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann. Clin. Lab. Sci. 30, 259-265 (2000).
126. Dittadi R, Zancan M, Perasole A, Gion M. Evaluation of HER-2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay. Int. J. Biol. Markers 16, 255-261 (2001).
127. Simon R, Nocito A, Hubscher T et al. Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer. J. Natl Cancer Inst. 93, 1141-1146 (2001). One of several papers indicating that HER-2/neu status in primary and metastatic tumors are uniform and do not appear to change over the course of the disease.
128. Vincent-Salomon A, Jouve M, Genin P et al. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 94, 2169-2173 (2002).
129. Xu R, Perle MA, Inghirami G et al. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and nonexpressing breast carcinomas and their synchronous benign, premalignant and metastatic lesions detected by FISH in archival material. Mod. Pathol. 15, 116-124 (2002).
130. Joshi MG, Lee AK, Loda M et al. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer 77, 490-498 (1996).
131. Gancberg D, Di Leo A, Cardoso F et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann. Oncol. 13, 1036-1043 (2002).
132. Pich A, Margaria E, Chiusa L. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival. J. Clin. Oncol. 18, 2948-2956 (2000).
133. Wang-Rodriguez J, Cross K, Gallagher S et al. Male breast carcinoma: correlation of ER, PR, Ki-67, HER2-neu and p53 with treatment and survival, a study of 65 cases. Mod. Pathol. 15, 853-861 (2002).
134. Rayson D, Erlichman C, Suman VJ et al. Molecular markers in male breast carcinoma. Cancer 83, 1947-1955 (1998).
135. Shpitz B, Bomstein Y, Sternberg A et al. Angiogenesis, p53 and c-erbB-2 immunoreactivity and clinicopathological features in male breast cancer. J. Surg. Oncol. 75, 252-257 (2000).
136. Bloom KJ, Govil H, Gattuso P et al. Status of HER-2 in male and female breast carcinoma. Am. J. Surg. 182, 389-392 (2001).
137. Stark A, Hulka BS, Joens S et al. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J. Clin. Oncol. 18, 267-274 (2000). Provocative study suggesting the possibility that low-level HER-2/neu overexpression in benign breast biopsies can predict a significant increased risk for those women that subsequent biopsies will be malignant.
138. Castellani R, Visscher EW, Wykes S et al. Interaction of transforming growth factor-α and epidermal growth factor receptor in breast carcinoma. Cancer 73, 344-349 (1994).
139. Umekita Y, Ohi Y, Sagara Y et al. Coexpression of epidermal growth factor receptor and transforming growth factor-α predicts worse prognosis in breast cancer patients. Int. J. Cancer 89, 484-487 (2000).
140. Yarden RI, Wilson MA, Chrysogelos SA. Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J. Cell. Biochem. Suppl. 36, 232-246 (2001).
141. Dumont N, Arteaga CL. Transforming growth factor-β and breast cancer: tumor promoting effects of transforming growth factor-β. Breast Cancer Res. 2, 125-132 (2000).
142. McCune BK, Mullin BR, Flanders KC et al. Localization of transforming growth factor-β isotypes in lesions of the human breast. Hum. Pathol. 23, 13-20 (1992).
143. Bonneterre J, Peyrat P, Beuscart R et al. Prognostic significance of insulin-like growth factor I receptors in human breast cancer. Cancer Res. 50, 6931-6935 (1990).
144. Oh Y. IGF-independent regulation of breast cancer growth by IGF binding proteins. Breast Cancer Res. Treat. 47, 283-293 (1998).
145. Shao ZM, Nguyen M, Barsky SH. Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 19, 4337-4345 (2000).
146. Rubin BP, Schuetze SM, Eary JF et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma. J. Clin. Oncol. 20, 3586-3591 (2002).
147. Yiangou C, Gomm JJ, Coope RC et al. Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance. Br. J. Cancer 75, 28-33 (1997).
148. Blanckaert VD, Hebbar M, Louchez MM et al. Basic fibroblast growth factor receptors and their prognostic value in human breast cancer. Clin. Cancer Res. 4, 2939-2947 (1998).
149. Faridi A, Rudlowski C, Biesterfeld S et al. Long-term follow-up and prognostic significance of angiogenic basic fibroblast growth factor (bFGF) expression in patients with breast cancer. Pathol. Res. Pract. 198, 1-5 (2002).
150. Smith K, Fox SB, Whitehouse R et al. Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. Ann. Oncol. 10, 707-713 (1999).
151. Kinoshita J, Kitamura K, Kabashima A et al. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res. Treat. 66, 159-164 (2001).
152. Linderholm BK, Lindahl T, Holmberg L et al. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res. 61, 2256-2260 (2001).
153. Foekens JA, Peters RA, Grebenchtchikov N et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 61, 5407-5414 (2001).
154. Manders P, Beex LV, Tjan-Heijnen VC et al. The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br. J. Cancer 87, 772-778 (2002).
155. Coradini D, Boracchi P, Daidone MG et al. Contribution of vascular endothelial growth factor to the Nottingham Prognostic Index in node-negative breast cancer. Br. J. Cancer 85, 795-797 (2001).
156. De Paola F, Granato AM, Scarpi E et al. Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer. Int. J. Cancer 98, 228-233 (2002).
157. MacConmara M, O'Hanlon DM, Kiely MJ et al. An evaluation of the prognostic significance of vascular endothelial growth factor in node-positive primary breast carcinoma. Int. J. Oncol. 20, 717-721 (2002).
158. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin. Diagn. Pathol. 10, 302-313 (1993).
159. Siitonen SM, Haapasalo HK, Rintala IS et al. Comparison of different immunohistochemical methods in the assessment of angiogenesis: lack of prognostic value in a group of 77 selected node-negative breast carcinomas. Mod. Pathol. 8, 745-752 (1995).
160. Callagy G, Dimitriadis E, Harmey J et al. Immunohistochemical measurement of tumor vascular endothelial growth factor in breast cancer. A more reliable predictor of tumor stage than microvessel density or serum vascular endothelial growth factor. Appl. Immunohistochem. Mol. Morphol. 8, 104-109 (2000).